Expression and diagnosis of transient receptor potential vanilloid1 in urothelium of patients with overactive bladder

Journal of Biological Regulators and Homeostatic Agents

Volumn 29, Issue 4, 2015, Pages 875-879

  Zhang, H Y ^a   Chu, J F ^a   Li, P ^a   Li, N ^a   Lv, Z H ^b  

^a Yantai Stomatological Hospital of Yantai   (China)

^b First Peoples Hospital of Jining   (China)

Author keywords

AOD; OAB; TRPV1; Urodynamics

Indexed keywords

VANILLOID RECEPTOR 1; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ARTICLE; BLADDER COMPLIANCE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; OPTICAL DENSITY; OVERACTIVE BLADDER; PROTEIN EXPRESSION; URODYNAMICS; UROTHELIUM; ADULT; CHEMISTRY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; URINARY BLADDER, OVERACTIVE;

ADULT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; TRPV CATION CHANNELS; URINARY BLADDER, OVERACTIVE; UROTHELIUM;

EID: 84965091967     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Na YQ, Ye ZQ, Sun G. Guideline on diagnosis and treatment of urological disease in China. Beijing: People’s Medical Publishing House 2011; 147-53.
2. Lori B, Karl-Erik A. Urothelial signaling. Physiol Rev 2013; 93(2):653-80.
3. Wang YL, Xu KX, Hu H. Prevalence of overactive bladder and the impact of overactive bladder on quality of life in Beijing adult women. Chinese J Urol 2010; 31(8):550-4.
4. Feng SQ. Expression and clinical significance of transient receptor potential vanilloid type 1 in female patient with overactive bladder. Wuhan: Huazhong University of Science and Technology 2013. http://cdmd.cnki.com.cn/Article/CDMD-104871014028853.htm.
5. Birder LA, Nakamura Y, Kiss S, et al. Altered urinary bladder function in mice lacking the vanillaoid receptor TRPV1. Nat Neuros 2002; 5(9):856-60.
6. Charrua A, Cruz CD, Cruz F, et al. Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder over activity in cystitis. J Urol 2007; 177(4):1537-41.
7. Wang ZY, Wang P, Merriam FV, et al. Lack of TRPV1 inhibits cystitis-induced increased mechanical sensitivity in mice. Pain 2008; 139(1):158-67.
8. Lori AB. Nervous network for lower urinary tract function. J Urol 2013; 20(1):4-12.
9. Juszczak K, Thor PJ. The basic neurophysiologic concept of lower urinary tract function - the role of vanilloid TRPV1 receptors of urinary bladder afferent nerve endings. Adv Clin Exp Med 2012; 21(4):417-21.
10. Frias B, Charrua A, Avelino A, et al. Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. BJU Int 2012; 110(8b):E422-E8.
11. Li M, Sun Y, Simard J, et al. Increased transient receptor potential vanilloid type 1 (TRPV1) signaling in idiopathic overactive bladder urothelial cells. Neurourl Urodyn 2011; 30(4):606-11.
12. Birder LA, Wolf-Johnston AS, Sun Y, et al. Alteration in TRPV1 and muscarinic (m3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiologica 2013; 207(1):123-9.
13. Krhut J, Gartner M, Havranek O, et al. Combination therapy with anti-cholinergics and alphablockers for the treatment of overactive bladder in female patients-pilot study. Ceska Gynekol 2009; 74(6):416-20.
14. Charrua A, Cruz CD, Narayanan S, et al. GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol 2009; 181(1):379-86.
15. Ha US, Park EY, Kim JC. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor over activity. Urology 2011; 78(3):721.
16. Kissin I, Szallasi A. Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials. Curr Top Med Chem 2011; 11(17): 2159-70.